Memorandum – Micro #250

To: UNCMC Attending and Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads, and Supervisors

From: Kevin Alby, PhD, Associate Director, Clinical Microbiology Laboratory

Melissa Miller, PhD, Director, Clinical Microbiology Laboratory

Herbert C. Whinna, MD, PhD, Medical Director
McLendon Clinical Laboratories

Date: July 16, 2025

Subject: Change in Antimicrobial Susceptibility Testing Methodology for Staphylococcus and Enterococcus spp.

Effective July 16, 2025, the UNC Medical Center Clinical Microbiology Laboratory will transition from the Kirby Bauer disk diffusion method to the Becton Dickinson Phoenix System for antimicrobial susceptibility testing of Staphylococcus and Enterococcus spp.

Antimicrobial susceptibility testing results will continue to be reported in accordance with guidelines set forth by the Clinical Microbiology Laboratory, the UNCMC Anti-Infective Subcommittee, and the Carolina Antimicrobial Stewardship Program to promote antimicrobial stewardship and utilization best practices.

Antimicrobials tested include: ampicillin, ceftaroline, clindamycin, daptomycin, doxycycline, erythromycin, gentamicin, levofloxacin, linezolid, nitrofurantonin, oxacillin, rifampin, trimethoprim/sulfamethoxazole, and vancomycin.

Questions can be directed to the Microbiology Lab 984-974-1805 or Dr. Kevin Alby at kevin.alby@unchealth.unc.edu